Compare Manchester United PLC (MANU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Natera Inc. Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.55B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16.1× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Natera Inc. Common Stock for 0 Days on average.
| MANU | NTRA | |
|---|---|---|
Market Cap | $3.55B | $57.03B |
Volume | 311,271 | 1,131,157 |
Sector | Media | Health |
52-Week High | $24.19 | $425.64 |
52-Week Low | $15.20 | $179.42 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.38B | $56.18B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.08, up 1.2% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but negative net income margins. Revenue reached $666.51M in 2025, though the company continues to post losses. Analyst sentiment is divided with 40% buy ratings, while technical indicators suggest potential near-term support at $21.
The investment case hinges on franchise valuation upside versus operational challenges. While trading at a discount to Forbes' $7.2B valuation estimate, persistent losses and high debt levels present significant risks. Champions League qualification offers revenue potential, but profitability remains elusive amid competitive pressures in European football.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
